Vantage logo

Circassia averts its cash crunch

Payment of an overdue $120m Astrazeneca milestone, plus two other obligations, has been met through a loan facility with undisclosed terms.

Vantage logo

Biotech flotations remain in high demand

Almost $2bn was raised by drug developers in the third quarter, a period that witnessed two of the largest flotations of pre-revenue companies in recent years.

Vantage logo

Where is the IPO class of 2014-15 now?

A golden age for biotech flotations yielded some spectacular blow-ups, but also saw several groups reward investors with premium-priced takeovers.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.